Comprehensive Assessment of Reactions to Pharmacogenetics in Complex Care Patients

Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · Jul 1, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how families of children with complex medical needs feel about a special type of genetic testing called pharmacogenetic testing. This testing helps doctors understand how a child might respond to certain medicines based on their genes. The study wants to see if, when cost and access are not problems, families are willing to have this testing done for their child, what challenges might still exist, and what their overall thoughts are about this kind of testing.

Children who might join this study are those with complex health conditions who receive care at the Cincinnati Children’s Complex Care Clinic. To be eligible, the child’s medical needs must meet a specific level of complexity, and their caregiver needs to be available during the clinic visit. If families choose to participate, the child will be offered the genetic test for free, and caregivers will be asked to fill out a survey. Some caregivers may also be invited to take part in a short interview to share their experiences and opinions. This study is currently not enrolling participants yet, but it aims to help improve how genetic testing can be used to personalize care for children with complex health needs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who score a 3 on the Pediatric Medical Complexity Algorithm
• • 2. Patients whose primary care providers are those at the Cincinnati Children's Complex Care Clinic
• • 1. Patients attending the Cincinnati Children's Hospital Complex Care Clinic for well child visit
• • 2. Patients attending the Cincinnati Children's Hospital Complex Care Clinic for chronic care management visits
• • 3. Legal Guardian is present at time of clinical visit
• Exclusion Criteria:
• • Patients attending the Complex Care Clinic for acute illness.
• • Patients who have previously received Pharmacogenetic Testing.
• • Patients deemed ineligible for approach by the clinical team.
• • Patients who are wards of the state.